In the past week, ARDX stock has gone down by -1.20%, with a monthly gain of 4.36% and a quarterly plunge of -26.38%. The volatility ratio for the week is 3.69%, and the volatility levels for the last 30 days are 5.79% for Ardelyx Inc The simple moving average for the past 20 days is 0.56% for ARDX’s stock, with a -15.72% simple moving average for the past 200 days.
Is It Worth Investing in Ardelyx Inc (NASDAQ: ARDX) Right Now?
The 36-month beta value for ARDX is also noteworthy at 0.89. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ARDX is 226.50M, and at present, short sellers hold a 11.72% of that float. The average trading volume of ARDX on August 19, 2024 was 4.55M shares.
ARDX) stock’s latest price update
Ardelyx Inc (NASDAQ: ARDX) has seen a decline in its stock price by -1.71 in relation to its previous close of 5.85. However, the company has experienced a -1.20% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-19 that ATLANTA, Aug. 19, 2024 (GLOBE NEWSWIRE) — A shareholder class action lawsuit has been filed Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). The lawsuit alleges that Defendants indicated that Ardelyx would apply to include its product, XPHOZAH, in the Transitional Drug Add-on Payment Adjustment (“TDAPA”) when, in fact, Ardelyx had not yet reached a firm decision concerning whether or not to apply to include XPHOZAH in TDAPA, and could not, in fact, decide whether or not to submit such an application to CMS until after Defendants first reviewed CMS’s proposed Calendar Year 2025 ESRD PPS rule, which was only issued on June 27, 2024. The price of Ardelyx’s stock fell following the news.
Analysts’ Opinion of ARDX
Many brokerage firms have already submitted their reports for ARDX stocks, with Piper Sandler repeating the rating for ARDX by listing it as a “Neutral.” The predicted price for ARDX in the upcoming period, according to Piper Sandler is $7 based on the research report published on July 02, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see ARDX reach a price target of $14. The rating they have provided for ARDX stocks is “Outperform” according to the report published on April 05th, 2024.
Raymond James gave a rating of “Strong Buy” to ARDX, setting the target price at $12 in the report published on December 18th of the previous year.
ARDX Trading at -3.33% from the 50-Day Moving Average
After a stumble in the market that brought ARDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.24% of loss for the given period.
Volatility was left at 5.79%, however, over the last 30 days, the volatility rate increased by 3.69%, as shares surge +1.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.17% lower at present.
During the last 5 trading sessions, ARDX fell by -0.60%, which changed the moving average for the period of 200-days by +46.46% in comparison to the 20-day moving average, which settled at $5.72. In addition, Ardelyx Inc saw -7.26% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARDX starting from DAVID P ROSENBAUM TODSUBJECT T, who proposed sale 20,000 shares at the price of $5.88 back on Aug 16 ’24. After this action, DAVID P ROSENBAUM TODSUBJECT T now owns shares of Ardelyx Inc, valued at $117,600 using the latest closing price.
RAAB MICHAEL, the President & CEO of Ardelyx Inc, sale 1,229 shares at $5.71 during a trade that took place back on Aug 12 ’24, which means that RAAB MICHAEL is holding 1,259,234 shares at $7,018 based on the most recent closing price.
Stock Fundamentals for ARDX
Current profitability levels for the company are sitting at:
- -0.28 for the present operating margin
- 0.86 for the gross margin
The net margin for Ardelyx Inc stands at -0.31. The total capital return value is set at -0.21. Equity return is now at value -48.23, with -23.49 for asset returns.
Based on Ardelyx Inc (ARDX), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at -0.82. The debt to equity ratio resting at 0.71. The interest coverage ratio of the stock is -24.24.
Currently, EBITDA for the company is -55.35 million with net debt to EBITDA at -1.14. When we switch over and look at the enterprise to sales, we see a ratio of 6.79. The receivables turnover for the company is 5.64for trailing twelve months and the total asset turnover is 0.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.21.
Conclusion
In summary, Ardelyx Inc (ARDX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
